Clinical Trials Directory

Trials / Completed

CompletedNCT03839745

Short-Term Cardiovascular Effects of E-Cigarettes: Influence of Device Power

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
16 (actual)
Sponsor
University of California, San Francisco · Academic / Other
Sex
All
Age
21 Years
Healthy volunteers
Accepted

Summary

This study will examine the short-term cardiovascular (CV) effects of e-cigarette device power in a randomized, crossover clinical and behavioral pharmacology study of experienced adult e-cigarette users (N=21). The specific aim is to determine the impact of e-cigarette power on nicotine pharmacology, systemic exposure to toxic volatile organic compounds (VOCs), and short-term cardiovascular effects.

Detailed description

This is a single-site, randomized, crossover study of experienced adult e-cigarette users to assess nicotine exposure, toxicant exposure, and the short-term CV effects of e-cigarette power. Three power levels will be assessed on all participants: 10, 15, and 20 watts. Hypothesis 1a: Systemic nicotine exposure and subjective measures of sensation in the throat, reward, and satisfaction will increase with increasing power in the e-cigarette device. Hypothesis 1b: Mercapturic acid metabolites of volatile organic compounds (VOCs), particularly acrolein, will increase with e-cigarette power. Hypothesis 1c: CV effects increase with higher power, and are manifested as changes in hemodynamic parameters, hormonal release, and biomarkers of endothelial function, platelet activation, inflammation, and oxidative stress.

Conditions

Interventions

TypeNameDescription
OTHERElectronic CigaretteE-cigarette Device: The delivery device will be a variable wattage all-in-one device with operating wattage of 7.0 - 75.0 W, which is inclusive of the three power levels we intend to study.

Timeline

Start date
2019-03-26
Primary completion
2021-12-31
Completion
2021-12-31
First posted
2019-02-15
Last updated
2024-07-01

Locations

2 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT03839745. Inclusion in this directory is not an endorsement.